🇺🇸 FDA
Pipeline program

HLD200 methylphenidate hydrochloride capsules

HLD200-112

Phase 3 small_molecule terminated

Quick answer

HLD200 methylphenidate hydrochloride capsules for Attention Deficit Hyperactivity Disorder is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
COLLEGIUM PHARMACEUTICAL, INC
Indication
Attention Deficit Hyperactivity Disorder
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials